首页> 外文期刊>Nanotechnology >NaYF4:Yb/Tm@SiO2-Dox/Cur-CS/OSA nanoparticles with pH and photon responses
【24h】

NaYF4:Yb/Tm@SiO2-Dox/Cur-CS/OSA nanoparticles with pH and photon responses

机译:Nayf4:Yb / TM / TM / CIO2-DOX / CUR-CS / OSA纳米粒子,具有pH和光子响应

获取原文
获取原文并翻译 | 示例
           

摘要

Stimulus-triggered drug delivery systems (DDSs) based on lanthanide-doped upconversion nanoparticles (UCNPs) have attracted significant attention for treating cancers due to their merits of high drug availability, precisely controlled drug release, and low side-effects. However, such DDSs usually exhibit a single stimulus-response, which may limit the efficiency of cancer treatment. To extend response types in a single DDS, we construct NaYF4:Yb/Tm@SiO2-doxorubicin (Dox)/curcumin (Cur)-chitosan (CS)/2-Octen-1-ylsuccinic anhydride (OSA) nanoparticles with core-shell structures. Our method is based on the exploration of the synergistic effect of UCNPs and multiple drugs. In particular, the NaYF4:Yb/Tm is used to convert near-infrared light to visible light, activating Cur photosensitizers to produce singlet oxygen for photodynamic therapy, while CS/OSA responds to a low pH environment to release cancer drugs, including Dox and Cur for chemotherapy through breaking a free carboxyl group. The results show that the UCNPs with a 40 nm diameter, 23 nm thick mesoporous SiO2, and 19/1 mol% Yb3+/Tm(3+)concentrations could continuously release Dox and Cur at a pH value of 6.5 within 6 h after the excitation of a 980 nm-wavelength CW laser. Our study provides a promising approach for developing efficient DDSs for cancer treatment.
机译:基于稀土掺杂上转换纳米颗粒(UCNP)的刺激触发给药系统(DDS)因其药物利用率高、药物释放精确、副作用小等优点,在治疗癌症方面引起了广泛关注。然而,这种DDS通常表现出单一的刺激反应,这可能会限制癌症治疗的效率。为了在单个DDS中扩展响应类型,我们构造了NaYF4:Yb/Tm@SiO2-具有核壳结构的阿霉素(Dox)/姜黄素(Cur)-壳聚糖(CS)/2-辛烯-1-基琥珀酸酐(OSA)纳米颗粒。我们的方法基于对UCNP和多种药物协同作用的探索。特别是,NaYF4:Yb/Tm用于将近红外光转换为可见光,激活Cur光敏剂以产生用于光动力疗法的单线态氧,而CS/OSA则对低pH环境作出反应,通过打破游离羧基释放癌症药物,包括用于化疗的Dox和Cur。结果表明,直径为40nm、厚度为23nm的介孔SiO2和浓度为19/1mol%Yb3+/Tm(3+)的UCNP在980nm波长的连续激光激发后6h内可在pH值为6.5的条件下连续释放Dox和Cur。我们的研究为开发用于癌症治疗的高效DDS提供了一种有希望的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号